98%
921
2 minutes
20
Objective: To explore the regulation of transdermal absorption of Secretio Bufonis (SB) and the effect of low frequency complex impulse current (LFCIC) on it.
Methods: By modifying three-chamber flow diffusion pool to develop a prototype LFCIC device for transdermal delivery, using high performance liquid chromatograph (HPLC) to determine the quantitative transdermal absorption of the amount of ingredients of SB, including bufalin, cinobufagin and resibufogenin, etc. and the transdermal absorption velocity was calculated.
Results: The chief ingredients of SB could be absorbed through skin, but the volume was low. Additional application of LFCIC could enhance the cumulative infiltration volume and velocity of transdermal diffusion. Difference appeared 2 hrs after and significant difference appeared 4 hrs after the application, and 13.8 Hz showed the optimal effect of transdermal delivery.
Conclusion: Chief ingredients of SB could be absorbed through transdermal medication, and LFCIC can evidently enhance the amount and velocity of transdermal absorption of SB.
Download full-text PDF |
Source |
---|
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Behçet's syndrome.
View Article and Find Full Text PDFInt J Pharm
September 2025
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, Nanjing, People's Republic of China; Engineering Research Center of Intelligent Theranostics Technology and Instruments, Ministry of Education, People's Republic of China. Electronic address:
Background: Ultrasound-assisted transdermal drug delivery, or sonophoresis, enhances skin permeability, offering a non-invasive alternative for drug administration. However, its clinical application remains limited because of an insufficient understanding of its underlying mechanisms and optimal parameters. This study investigates the factors influencing ultrasound-enhanced drug absorption and examines its biological effects on skin structures and HaCaT cells, providing a comprehensive analysis of its mechanisms.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, China. Electronic address:
Ultraviolet (UV) radiation-induced photodamage remains a critical dermatological challenge, necessitating natural alternatives to synthetic photo-protectants. This study aimed to evaluate the anti-photodamage potential of fermented Sphagnum moss filtrate (SMFF) through integrated metabolomic, cellular and in vivo analyses. Untargeted metabolomics identified 933 metabolites, with fermentation significantly enriching taurine, glycine derivatives and phenolic acids while activating glycine/serine and taurine/hypotaurine metabolic pathways critical for redox homeostasis.
View Article and Find Full Text PDFDrug Metab Pharmacokinet
July 2025
Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Subcutaneous administration is widely used as a clinical administration route for Fc-fusion proteins. However, predicting bioavailability (BA) in humans after subcutaneous administration is challenging due to multiple factors involved in the absorption process. This study aimed to elucidate the impact of degradation on the BA of Fc-fusion proteins.
View Article and Find Full Text PDF